-
Everett Labs acquires Quinnova Pharmaceuticals from Amneal Enterprises
CHATHAM, N.J. — Everett Labs has acquired Quinnova Pharmaceuticals from Amneal Enterprises, Everett said Monday.
Everett Labs, a subsidiary of Spain-based Exeltis, said the purchase would help it expand into the U.S. dermatology and women's health markets. Financial terms of the deal were not disclosed.
-
Novartis, Incyte drug produces higher survival rates in patients with myelofibrosis
BASEL, Switzerland — A drug marketed by Novartis and Incyte Corp. extends the lives of patients with a life-threatening blood cancer to a greater extent than conventional therapy or placebo, according to results of a late-stage clinical trial.
Novartis announced the results of two phase-3 studies of Jakavi (ruxolitinib) in patients with myelofibrosis, presenting them at the American Society of Hematology's annual meeting and exposition in New Orleans.